PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
21 October 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. SIGNS LETTER OF INTENT TO COMMERCIALIZE PRODUCTS
FOR THE PERSONAL SKIN CARE MARKETS THROUGH 1,250 RETAIL OUTLETS
(Charlottesville, VA, 21 October 2008) – PluroGen Therapeutics, Inc. today announced the signing of a
Letter of Intent with a new corporate partner in the personal skin care product markets for the companies
to commercialize new products based on PluroGen’s proprietary technologies to their channel of 1,250
retail outlets. The details and scope of the commercial relationship, for strategic reasons, will remain
confidential until market launch, which is targeted in 2009.
Neal G. Koller, President & CEO of PluroGen, in announcing this new partnership, commented that “this
Letter of Intent creates another important new market opportunity and outlet for our products and
technologies, in this case personal skin care products into an expanding 1,250 retail outlet channel, with a
strong partner capable of bringing significant profit and revenue to PluroGen in 2009. Developing products
based on our technologies for these new markets is another very strategic forward step in our plan to
expand the utility and opportunity for our technologies. This relationship provides additional confirmation
of the value of our products and technologies, and, of our significant multiple market opportunities.”
About PluroGen Therapeutics, Inc.
PluroGen is a wound healing company commercializing its patent-protected gel technology platform that
provides superior and differentiated physical and bio-impact benefits to wound healing. The technology is
configurable to deliver drug and non-drug compounds as protected and advanced therapeutic products for
simple and complex skin care, burn and wound healing. PluroGen’s product pipeline targets improved,
protected therapies for the 6 areas of treatment in tissue healing (cleansing, infection, pain, inflammation,
tissue salvage, tissue regeneration).
PluroGen’s first gel, PluroGel™, is being used initially in skin and wound cleansing products and for two
branded topical antimicrobial products, PluroGel™ Silver Sulfadiazine and PluroGel™ TAG. PluroGel™ TAG is
currently in routine use at the University of Virginia Medical Center, having shown superior results on more
than 2,000 patients in two different patient populations, severe burns and chronic wounds. The PluroGen
management and operational teams, Boards and Principal Investigators are recognized global clinical and
commercial leaders in PluroGen’s target markets of burn and wound care and in the life sciences industry.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.
com
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or
otherwise.
President & CEO
21 October 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. SIGNS LETTER OF INTENT TO COMMERCIALIZE PRODUCTS
FOR THE PERSONAL SKIN CARE MARKETS THROUGH 1,250 RETAIL OUTLETS
(Charlottesville, VA, 21 October 2008) – PluroGen Therapeutics, Inc. today announced the signing of a
Letter of Intent with a new corporate partner in the personal skin care product markets for the companies
to commercialize new products based on PluroGen’s proprietary technologies to their channel of 1,250
retail outlets. The details and scope of the commercial relationship, for strategic reasons, will remain
confidential until market launch, which is targeted in 2009.
Neal G. Koller, President & CEO of PluroGen, in announcing this new partnership, commented that “this
Letter of Intent creates another important new market opportunity and outlet for our products and
technologies, in this case personal skin care products into an expanding 1,250 retail outlet channel, with a
strong partner capable of bringing significant profit and revenue to PluroGen in 2009. Developing products
based on our technologies for these new markets is another very strategic forward step in our plan to
expand the utility and opportunity for our technologies. This relationship provides additional confirmation
of the value of our products and technologies, and, of our significant multiple market opportunities.”
About PluroGen Therapeutics, Inc.
PluroGen is a wound healing company commercializing its patent-protected gel technology platform that
provides superior and differentiated physical and bio-impact benefits to wound healing. The technology is
configurable to deliver drug and non-drug compounds as protected and advanced therapeutic products for
simple and complex skin care, burn and wound healing. PluroGen’s product pipeline targets improved,
protected therapies for the 6 areas of treatment in tissue healing (cleansing, infection, pain, inflammation,
tissue salvage, tissue regeneration).
PluroGen’s first gel, PluroGel™, is being used initially in skin and wound cleansing products and for two
branded topical antimicrobial products, PluroGel™ Silver Sulfadiazine and PluroGel™ TAG. PluroGel™ TAG is
currently in routine use at the University of Virginia Medical Center, having shown superior results on more
than 2,000 patients in two different patient populations, severe burns and chronic wounds. The PluroGen
management and operational teams, Boards and Principal Investigators are recognized global clinical and
commercial leaders in PluroGen’s target markets of burn and wound care and in the life sciences industry.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.
com
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or
otherwise.